Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease
Could Merck/Kelun Come Out On Top?
The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers.
